INVESTORS PRESENTATION MAY 02, 2019 MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL PRIVILEGED & CONFIDENTIAL
Confidentiality Statement and Legal Disclaimer This Memo is confidential. Unauthorized reproduction or distribution of it or any of its contents in any form or under any circumstances without prior written consent is prohibited. The Recipient is responsible for returning all copies of the Memo immediately upon request of the Company. The information contained herein is publicly available from directories, publications, and websites, as mentioned in the body and the footnotes where possible or appropriate. In some cases, non-publicly available information was used, including independent research, studies or paid services from individuals and organizations. While the information set forth herein is deemed by the Company to be accurate, the Company shall not be held liable for the accuracy of or any omissions from this Memo or for any other written or oral communication transmitted to the Recipient and any other party in the course of its evaluation of transactions involving the Company. The information contained in the Memo will require careful scrutiny, verification and due diligence efforts from the Recipients of the Memo. Any person or entity seeking to make an investment in the business should not rely on the information set forth in the Memo as complete. In addition, the analyses contained herein do not claim to be appraisals of the assets or the valuation of any entity. The business makes no guarantees regarding any benefits received from an investment, nor the legal, tax or accounting effects of any transaction; and this Memo does not constitute an offer to sell, or a solicitation of an offer to buy securities. In furnishing the Memo, the Company undertakes no obligation to provide Recipients of the Memo with access to any additional information or to update this Memo or to correct any inaccuracies that may be contained herein. There exists substantial information with respect to the business and its future prospects, and there are a substantial number of risks associated with an investment in the business, which are not set forth in the Memo. Furthermore, the potential fulfillment of “forward looking statements” contained in the Memo are subject to change due to unexpected events, market shifts, or circumstances that cannot be known at this time. Forward looking statements are based on expectations, estimates and projections at the time the statements were made that involve a number of economic, business, and numerous risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in the Memo may be identified through the use of words such as, but not exclusively to: “expects,” “will,” “anticipates,” “estimates,” “believes,” or statements indicating certain actions “may,” “could,” or “might” occur. Such estimates and projections are subject to significant uncertainties beyond the control of the Company. Although such projections are believed to be realistic, no representations are made as to their ultimate attainability. MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
Executive Summary MYM Nutraceuticals is establishing CBD-rich hemp and cannabis cultivation facilities around the world Focused on becoming a leading global supplier of CBD-rich isolate Cultivation, extraction, distribution, and unique brands MYM currently has four CBD-rich hemp cultivation and extraction projects, two medical cannabis cultivation facilities, and three CBD-rich isolate product distribution offices across the globe MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
If MYM sells bulk CBD-rich hemp biomass, gross profits are forecasted to be the following: 2019 grow season – 1.1 million lbs total, 610 acres total, $21.1 million MYM share of gross profits CBD is a phytocannabinoid extracted from the cannabis plant. 2020 grow season – 5.4 million lbs total, 3,285 acres total, $80.5 million MYM share of gross profits CBD does not contain THC and does not have the same psychoactive side effects. If MYM converts the CBD-rich biomass to isolate, gross profits are forecasted to be the following: 2019 grow season – 49,839 lbs isolate total, $55.0 million MYM share of gross profits CBD-rich hemp and its by-products are experiencing explosive growth on a global scale. 2020 grow season – 246,192 lbs isolate total, $193.5 million MYM share of gross profits Shortage of quality product and high prices where available. For the current cannabis operations, the company forecasts the following: 2019 fiscal year – 485 lbs, 4,500 sq ft, $1.0 million gross profits The Hemp Farming Act of 2018 (the “Farming Act”) removed hemp from its controlled substances list. 2020 fiscal year – 3,615 lbs, 12,500 sq ft, $7.3 million gross profits MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
Global Operations MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
HEMP OVERVIEW & PROJECTS MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
Hemp Overview CBD is a phytocannabinoid extracted from the genus Cannabis CBD-rich hemp contains very low traces of THC and does not have the same psychoactive side effects CBD-rich hemp and its by-products are experiencing explosive growth on a global scale Shortage of quality product and high prices where available The Hemp Farming Act of 2018 (the “Farming Act”) removed hemp from its controlled substances list MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
SASKATCHEWAN, CANADA Cultivate 450 acres of CBD-rich hemp in Saskatchewan, Canada for the 2019 growing season Expand to 3000 acres of certified organic CBD-rich hemp for 2020 growing season Team has proven track record of successful CBD- rich hemp cultivation projects MYM share of gross profits for biomass forecasted to be $13.9 million for 2019 and $70.8 million for 2020 MYM share of gross profits for CBD isolate forecasted to be $31.2 million for 2019 and $154.6 million for 2020 3000 acres of CBD-rich hemp cultivation project in Saskatchewan, Canada MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
NEVADA, USA Cultivate 120 acres of CBD-rich hemp for the 2019 growing season Agreement allows MYM to renew for 2020 growing season Elite will plant, grow, harvest, and extract the CBD- rich hemp into isolate Team has proven track record of successful CBD- rich hemp cultivation projects MYM share of gross profits for isolate forecasted to be $5.4 million for 2019 and $3.9 million for 2020 CBD-rich hemp production agreement with immediate revenue generating potential MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
NAVAJO NATION, USA Cultivate 100 acres of CBD-rich hemp for the 2019 growing season Expand to 225 acres of CBD-rich hemp for the 2020 growing season Expansion plans for up to 3000 acres within five years MYM share of gross profits for biomass forecasted to be $4.6 million for 2019 and $7.6 million for 2020 MYM share of gross profits for isolate forecasted to be $17.7 million for 2019 and $30.1 million for 2020 Large-scale hemp cultivation project on resource rich Navajo land MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
MEDELLIN, COLOMBIA First-mover advantage in Colombia purchasing 80% of Colombia Organica Colombia Organica hold 3 licenses which include production, cultivation and exportation Application submitted to register 102 cannabis strains Cultivate 25 acres of CBD-rich hemp. MYM share of gross profits for isolate forecasted to be $4.8 million for 2020 Expansion plans for 2020 Launching point to South American operations with initial 25 acre greenhouse grow MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
CANNABIS OVERVIEW & PROJECTS MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
Cannabis Overview On October 17, 2018, Canada became the first G7 country to legalize cannabis for adult recreational use Canadian cannabis companies were afforded a first-mover advantage in a trend that is certain to continue on a global scale Governments around the world are re-evaluating cannabis regulations MYM is currently in the final stages of licensing two medical cannabis facilities in Quebec, Canada These facilities will produce super premium, high quality cannabis for the Quebec medical market MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
LAVAL, CANADA Indoor cultivation of small batch, ultra premium, indoor cannabis Expansion plans to 37,000 sq ft. Gross profits forecasted to be $990,000 for 2019 Gross profits forecasted to be $7.38 million for 2020 “Craft” cannabis and premium seed sales Small batch, ultra premium, indoor cannabis production facility MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
WEEDON, CANADA Plans to build up to 1.5 million square foot greenhouse on 329 acres of land Initial buildout of an 8,000 sq ft greenhouse and 6,000 sq ft processing centre and office space is complete Currently building 22,000 square foot greenhouse Total annual production at full capacity is expected to exceed 160,000 kgs Potentially one of the largest greenhouse cultivation projects in Canada MYM NUTRACEUTICALS INC. CSE: MYM OTC: MYMMF PRIVILEGED & CONFIDENTIAL
Recommend
More recommend
